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Multimodal treatment was used in 23 (85%): chemotherapy and radiation
in 8 (34%), chemotherapy and surgery in 5 (21%), chemotherapy, surgery
and radiation in 10 (43%). Nine patients with non-axial disease and 5
patients with axial disease had surgery (p¼0.03). Median follow-up for
the treated patients was 27.5-months (Range:1-90).Out of 23 children
who received curative treatment-11(47%) were alive &well, 5 (21%) were
on treatment, 2 (0.08%) abandoned treatment & 4 (0.17%) had relapse/
refractory disease; one (0.04%) patient died from treatment related
toxicity. Five-year overall survival and event-free survival were 40% &
52%, respectively. Axial location (p¼0.27), metastatic disease (p¼0.74),
and lack of surgery (p¼0.34) were not statistically predictive of relapse/
progression, probably due to low numbers of patient and limited duration
of follow up.
Conclusions: In spite of a similar clinical proﬁle and disease stage, the
outcome of Ewings sarcoma in our patients simulates that reported in
Indian studies, however lags behind Western statistics. Reducing aban-
donment by tracking defaulters and providing support, using a uniform
protocol, and improving supportive care, were identiﬁed as plausible steps
to improve outcomes.ST-1_V1.2
CLINICAL EXPERIENCE AND OUTCOME OF HEPATOBLASTOMA IN
CHILDREN: A 9-YEAR RETROSPECTIVE STUDY
Sanjeev Khera, Amita Trehan, K.L.N. Rao, Deepak Bansal, Nandita
Kakkar, Radhika Srinivasan. PGIMER, Chandigarh, India
Background: Hepatoblastoma (HBL) is the most common primary liver
tumor in children. Metastatic disease at presentation, alphafetoprotein
(AFP) less than 100 ng/ml, PRETEXT IV, undifferentiated histology are usual
poor prognostic markers. Neoadjuvant chemotherapy with surgical
resection has led to increased survival of these patients
Aim: This single centre study assesses the outcome and the factors
affecting prognos is of children treated as per guidelines of SIOPEL3 in a
low middle income country (LMIC).
Materials & Methods: Forty children with HBL treated as per protocol
from Jan 2007 to Dec 2015 were analyzed. The diagnosis was established
by imaging, AFP and histology/cytology.
Results: 27 boys & 13 girls; median age 12 months (2-120) with a mean
symptom diagnosis interval (SDI) of 5.3 weeks (1-24) were diagnosed.
Multifocal involvement was seen in 7/40. Median AFP at diagnosis: 16500
ng/ml (3-406198). 2 had AFP less than 100 ng/ml. Mean platelet count at
diagnosis was 701375/cmm (95% CI 595510.80 to 807239.20).7 (17.5%)
had metastatic disease (6 lungs; 1 adrenal). PRETEXT: I-IV: 6, 13, 11 & 9.
Nineteen: high risk (HR) disease (7 with SDI more than 8 weeks) 13/40
defaulted/refused therapy. All cases received neoadjuvant chemotherapy.
3 deaths occurred prior to surgery. 25 underwent surgery; complete
resection (CR): 18/25 [14 : well; 3 relapsed, 1 died]. 7 cases subtotal
resection : 2 : well, 4 had persistant disease and 1 death.2/3 childrenwho
received salvage chemotherapy with Docetaxel had no response. HR
patients had a poorer outcome (p¼.012), more multifocal disease
(p¼.0395) and signiﬁcantly lower CR (p¼.0016) as compared to standard
risk patients. On comparing well Vs relapsed/residual disease cases;
there was no difference in AFP levels, volume reduction after neo-
adjuvant therapy, metastasis, & histopathology (p¼ns). Relapsed/resid-
ual disease was signiﬁcantly higher in those with higher mean age (24
mth Vs 12 mth); PRETEXT IV & multifocal disease (p¼0.02 & 0.04).
16 of 27 patients are presently well; median follow up being 48.3 months
(7-101).
Conclusion: 59 % (16/27) of cases whowere treated are well. 86%of SR HBL
had good outcome. Higher age at presentation, multifocality and high
PRETEXT was associated with poor outcome. HR patients had a longer SDI.
Docetaxel as a salvage therapy was not effective. Liver transplant, not
available at our centre, would have helped the children with incomplete
resection. Delayed referral and diagnosis remains a problem in LMIC's as
evident by greater SDI in those with HR disease.ST-1_V1.3
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Abstract
Background: Advances in chemotherapy, liver resection techniques and
pediatric liver transplantation have vastly improved survival in children
with hepatoblastoma (HB). These are best managed by a multidisciplinary
team in a setting where all treatment options are available. Until recently
this was difﬁcult to achieve in India.
Methods: Review of all children (< 16yrs) with HB treated in a pediatric
liver surgery & transplantation unit between Jan 2011 and July 2016. Data
regarding the clinical presentation, pre-operative management, surgical
treatment, postoperative course and outcomes was extracted from a pro-
spectively managed database.
Results: Thirty children were treated for HB during the study period.
Nine children were PRETEXT 4, 7 were PRETEXT 3, 13 were PRETEXT 2
and one was PRETEXT 1. All children received neoadjuvant chemo-
therapy before surgery followed by adjuvant chemotherapy. Nineteen
children had complete resection, while six underwent primary living
donor liver transplantation. There were 6 mortalities including 5 chil-
dren who poorly responded to chemotherapy with progressive tumor
extension. At a median follow-up of 30 months, two children who un-
derwent resection and one child who underwent liver transplant had
disease recurrence.
Conclusion: Improved outcomes can be achieved in childrenwith HB even
in countries with limited resources when they are managed by multidis-
ciplinary teams with expertise in pediatric oncology, liver resection and
liver transplantation.ST-1_V1.4
CLINICOPATHOLOGICAL PROFILE OF PEDIATRIC MEDULLOBLASTOMA
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Introduction: Medulloblastoma is the second most common primary
malignant brain tumour in children. We present the clinic-pathological
proﬁle of children seen in a pediatric hematology/Oncology unit over a
ten-year period.
Method: Clinical and laboratory data of children with medulloblastoma
who attended the pediatric hematology/oncology unit of CMC, Vellore
from 2004 to 2014 were retrieved from the medical records and reviewed.
Results: 76 children, 49 boys and 27 girls, with mean age at presentation
8.5±3.45 years. 7 were < 3 years and 22 were >10years. Headache (86%)
vomiting (79%) and ataxia (58%) were the common symptoms. The mean
duration from onset of symptoms to diagnosis was 2.7 ±2.2 months with
78% diagnosed within 3 months. All children presented to the neurosur-
gical team at ﬁrst visit. 30% required emergency CSF diversion procedure.
All children underwent upfront surgical excision; 30 had residual tumour
>1.5cm2. Risk stratiﬁcation based on age at presentation, volume of re-
sidual tumour and presence of metastatic disease, showed 43/76 to be in
the high risk category.
Histological classiﬁcation showed the following: classic 22 (37%), desmo-
plastic 19 (33%), medulloblastoma with extensive nodularity9 (16%), large
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S28cell 5 (9%) and anaplastic 2 (4%). 19 cases were only reported as medul-
loblastomaWHO IV. Using immunohistochemical marker beta catenin and
histology 43 tumours were subdivided into WNT (26), SHH (13), non-
WNTnonSHH (4) groups.
Conclusion: There was an obvious male predominance in this group. 78%
of cases were diagnosed within 3 months of onset of symptoms. 57% of
cases had high risk disease.ST-1_V1.5
INFLAMMATORY MYOFIBROBLASTIC TUMORS: A TALE OF THREE
STORIES
J.H. Teo, M.Y. Chan, D.W.Q. Lian, R. Bhattacharyya, P. Iyer. Haematology and
Oncology Service, Department of Paediatric Subspecialties, KK Women's and
Children's Hospital, Singapore
Background/Objectives: Inﬂammatory myoﬁbroblastic tumors (IMT)
are unusual intermediate malignant potential tumors that occur in soft
tissues and visceral organs of children and young adults. The tumors
consist of myoﬁbroblastic spindle cells and inﬂammatory cells. These
tumors can be locally aggressive, recur or rarely metastasize. There are
no clear consensus guidelines on treatment for patients with such tu-
mors. We describe three cases from our tertiary academic paediatric
institute in Singapore.
Design/Methods: A retrospective analysis of paper, electronic records, and
histology slides of patients diagnosed with IMT in our hospital between
1997-2012 was performed.
Results: Three patients with IMT were identiﬁed. All patients had intra-
abdominal tumors (omentum, spleen, supra-renal) with one patient also
having a concurrent IMT located in the left hemi thorax. Histopathological
ﬁndings reported positivity for ALK -1 stain in 2 patients. Primary com-
plete surgical resection of the tumors was attempted without success.
And hence adjuvant chemotherapy was administered in all cases. A va-
riety of chemotherapeutic agents in combinations were used as per
physician preference. Two patients also received monotherapy with non-
steroidal anti-inﬂammatory drug (NSAID) when the tumors did not
respond to chemotherapy. Both the patients on NSAID therapy showed
transient partial responses. One patient with aggressive IMT died due to
neutropenic sepsis. The mTOR inhibitor sirolimus was started on one
patient who is now alive with stable disease three years after
commencement. A local recurrence in one patient was treated with
further surgery and she now remains in complete remission. These two
patients remain on active follow up.
Conclusion: Sirolimus appears to offer disease control in children with
inoperable or resistant IMT. Further studies are required to understand and
manage these fascinating mesenchymal tumors better.ST-1_V1.6
OUTCOMES OF SURGERY FOR RENAL TUMOURS WITH INTRAVASCULAR
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M. Bhagat, S. Qureshi, S. Kembhavi, T. Vora, M. Ramadwar,
G. Chinnaswamy, S. Laskar. Tata Memorial Hospital, Mumbai, India
Aim: The aim of this study was to review themanagement of childrenwith
Wilms' tumour who had intravascular thrombus.
Material and methods: The data regarding presentation, treatment
received, surgical management, complications and outcomes were evalu-
ated. All patients received neoadjuvant chemotherapy except in two.
Results: The study cohort included 31 patients with intravascular
thrombus treated from 2006 to 2015. The thrombus extent at presentation
was: Infrahepatic inferior vena cava (IVC) -19, retrohepatic IVC -6, supra-
hepatic IVC -1 and Atrium -5. There was complete clearance of IVC in 11/31
patients with neoadjuvant chemotherapy. Regression of the thrombus
occurred in 17/31 patients. Due to regression of the tumor thrombus from
the atrium, cardiopulmonary bypass could be avoided in 2 patients. In all
patients the thrombus had to be dissected off from the tunica intima due todense ﬁbrosis around it. The only major complication was massive
bleeding in one patient with atrial thrombus. There was no perioperative
or 30-day postoperative mortality. The 3-year OS and EFS was 89.3% and
77.8% respectively.
Conclusions: Intravascular tumor thrombus extension has favourable
outcomes after contemporary multidisciplinary treatment. Chemotherapy
aids in surgery, with tumor regression and thus may obviate the need of
cardiopulmonary bypass in atrial thrombus.ST-1_V1.7
PEDIATRIC MEDULLOBLASTOMA: EXPERIENCE AT TATA MEDICAL
CENTER, KOLKATA
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Chandra, Mayur Parihar, Arpita Bhattacharyya. Tata Medical Center,
Kolkatta, India
Background: Medulloblastoma is the commonest pediatric malignant
brain tumor. Cure-rates of ~75% have been achieved in the West. Indian
centers have reported inferior survival. The aim of the studywas to analyze
the clinical proﬁle and outcome in children treated at a new referral cancer
hospital in Eastern India.
Methods: A retrospective analysis of case records of children (<18-
years) diagnosed with medulloblastoma, between June 2011-July 2016,
was performed. Modiﬁed Chang staging, using MRI of brain and spine,
and analysis of cerebrospinal ﬂuid was used. Children aged >3-years,
with post-operative residual tumor <1.5cm2, M0 stage, and non-large
cell/anaplastic histology, were classiﬁed as ‘standard-risk.’ ‘Standard-
risk’ and ‘high-risk’ children received cranio-spinal irradiation with
23.4Gy in 13 fractions, and 36Gy in 20 fractions, over 3.5-4 weeks,
respectively. Posterior fossa and/or tumor bed was boosted to a total
dose of 55.8Gy in 31 fractions. Following radiation, ‘standard-risk’
children received 8 cycles of cisplatin, lomustine and vincristine. ‘High-
risk’ patients received 8 cycles of cisplatin, cyclophosphamide and
vincristine, or, ifosfamide, cisplatin and etoposide (physician's discre-
tion). Analysis was performed using IBM-SPSSv20. Kaplan-Meier
method was used for survival analysis.
Results: Twenty-six children were enrolled. Median age was 6-years
(range:0.9-13.5); 4 (15.3%) were 3-years at diagnosis. 54% were males.
Median symptom-interval was 3.7-months (range: 1-12). Symptoms
included vomiting (20; 77%), headache (17; 65%), unsteadiness (14; 54%)
and cranial nerve palsy (2; 7%). Location of tumor (n¼22) included
midline, cerebellum (9; 41%), lateral cerebella (5; 23%) and roof of 4th
ventricle (8; 36%). Modiﬁed Chang staging: T (n¼17): T1 (1; 6%), T2 (2;
12%), T3 (5; 29%), T4 (9; 53%), and, M (n¼22): M0 (9; 41%), M1 (3; 13.5%),
M3 (7; 32%), M4 (3; 13.5%).
Seven (32%) childrenwere standard-risk and 15 (68%) were high-risk; data
was missing for the rest. Eight (31%) refused treatment. Extent of surgical
resection (n¼16) included gross total resection: 7 (44%), near total resec-
tion: 3 (18.5%), sub-total resection: 6 (37.5%). A ventriculo-peritoneal shunt
had been inserted in 11/20 (55%). Median time from surgery to initiation of
radiotherapy was 41-days (range:34-51).
At a median follow-up of 28.5-months (range:0.1-55), 12 (46.5%) were
alive, 9 (35%) of whom had completed, and 3 (11.5%) were on treatment; 3
(11.5%) had relapse/progression, 2 (7.5%) had abandoned treatment, while
1 (3.5%) had received palliative care. Among the 4 children3-years, 1 had
disease progression and 3 refused treatment. 4-year EFS (for those who
completed therapy was 66.1 ± 1.2%; standard-risk: 100%, high-risk: 45 ±
1.8%. Treatment-related complications included posterior fossa syndrome
(7; 39%), sepsis (4; 22%), shunt obstruction (1; 5%) and hearing loss (4;
22%).
Conclusion: Limitations of the study included high prevalence of treat-
ment-refusal/abandonment (10; 38%) and non-availability of molecular
subtyping for more accurate risk stratiﬁcation. Nevertheless, this study
shows that when properly diagnosed and treated, the outcomes of chil-
drenwith standard risk medulloblastoma in India are comparable with the
west. Further improvements in outcome require providing social support
to reduce treatment-refusal/abandonment, standardization of care for
